Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Farmers Insurance
Chinese Patent Office
US Department of Justice

Generated: May 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,993,578

« Back to Dashboard

Title:Methods for treating HCV
Abstract: The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).
Inventor(s): Bernstein; Barry M. (Mequon, WI), Menon; Rajeev M. (Buffalo Grove, IL), Khatri; Amit (Waukegan, IL), Mensing; Sven (Mannheim, DE), Dutta; Sandeep (Lincolnshire, IL), Cohen; Daniel E. (Wilmette, IL), Brun; Scott C. (Green Oaks, IL), Awni; Walid M. (Green Oaks, IL), Dumas; Emily O. (Libertyville, IL), Klein; Cheri E. (Northbrook, IL), Podsadecki; Thomas J. (Northbrook, IL)
Assignee: AbbVie Inc. (North Chicago, IL)
Filing Date:Dec 23, 2013
Application Number:14/138,449
Claims:1. A method of treatment for HCV, comprising administering at least two direct acting antiviral agents (DAAs) to a patient infected with HCV genotype 1, wherein said treatment lasts for 8 or 12 weeks and does not include administration of either interferon or ribavirin to said patient, wherein said at least two DAAs comprise Compound 1 ##STR00010## Compound 4 ##STR00011## and PSI-7977, and wherein Compound 1 is administered with ritonavir.

2. The method of claim 1, wherein said patient is a treatment-naive patient.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Daiichi Sankyo
Express Scripts
Harvard Business School
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.